Is there an approved injectable medication named "Micc" for weight loss?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

"MICC" Weight Loss Shot: No FDA-Approved Injectable Medication Exists

There is no FDA-approved injectable medication named "MICC" for weight loss. The term "MICC" appears to refer to compounded formulations marketed by some wellness clinics, typically containing methionine, inositol, choline, and cyanocobalamin (vitamin B12), but these are not FDA-approved medications and lack rigorous clinical evidence for efficacy or safety in weight management.

What You Should Know About "MICC" Injections

The Reality of Compounded "MICC" Products

  • These are not FDA-approved medications for weight loss or any other indication
  • No high-quality clinical trials demonstrate their effectiveness for weight reduction
  • The individual components (methionine, inositol, choline, B12) have no established mechanism for meaningful weight loss
  • These products fall outside standard evidence-based obesity management guidelines

FDA-Approved Injectable Weight Loss Medications

If you're seeking evidence-based injectable weight loss therapy, consider FDA-approved options instead:

First-Line Injectable Options (2023 Guidelines)

Semaglutide (subcutaneous, 2.4 mg weekly) - FDA approved 2021

  • Achieves 14.9-16.0% weight loss at 68 weeks versus 2.4-5.7% with placebo 1
  • Reduces cardiovascular events (HR 0.80; 95% CI 0.72-0.90) in patients with existing CVD 1
  • Must be used lifelong; weight regain of 6.9-11.6% occurs after discontinuation 1

Tirzepatide (subcutaneous, weekly) - FDA approved November 2023

  • Achieves 15.0-20.9% weight loss at 72 weeks depending on dose (5-15 mg) versus 3.1% with placebo 1
  • Superior to semaglutide by approximately 5.1% additional weight loss 1
  • Dual GLP-1 and GIP receptor agonist mechanism

Liraglutide (subcutaneous, 3.0 mg daily) - FDA approved 2014

  • Achieves 8.0% weight loss at 56 weeks versus 2.6% with placebo 1
  • Less effective than semaglutide but may be preferred due to cost/availability 1

Clinical Algorithm for Injectable Weight Loss Therapy

Indications (per 2023 JAMA Guidelines)

  • BMI ≥30 kg/m², OR
  • BMI ≥27 kg/m² with weight-related complications (diabetes, hypertension, dyslipidemia, CVD) 1
  • Inadequate response to lifestyle modifications alone

Medication Selection Priority

  1. Tirzepatide 15 mg weekly - Highest efficacy for weight loss 1
  2. Semaglutide 2.4 mg weekly - Best cardiovascular outcomes data, second-best weight loss 1
  3. Liraglutide 3.0 mg daily - Consider when cost/availability limits access to GLP-1 agonists 1

Essential Counseling Points

  • All medications require concurrent lifestyle modification (reduced-calorie diet, 150-200 min/week physical activity) 1
  • Lifelong therapy is necessary - significant weight regain occurs upon discontinuation 1
  • Monitor for gastrointestinal adverse events (nausea, vomiting, diarrhea)
  • Pregnancy testing required for women of childbearing potential

Critical Pitfalls to Avoid

Do not recommend or prescribe compounded "MICC" injections:

  • No evidence base for efficacy
  • No FDA oversight for safety or quality
  • Diverts patients from proven therapies
  • May delay appropriate evidence-based treatment

Do not use FDA-approved medications without lifestyle intervention - medications must be combined with dietary changes and physical activity for optimal outcomes 1

Do not discontinue effective therapy prematurely - weight loss medications require long-term use; stopping leads to substantial weight regain 1

References

Related Questions

With an A1c of 10.6% while taking insulin glargine (Lantus) 42 units twice daily and insulin aspart for meals, how much should the basal insulin dose be increased?
How often should I receive the meningococcal conjugate (Men‑C) vaccine?
In opioid poisoning, how should the patient be monitored for worsening signs and what specific signs indicate deterioration?
What is the recommended management for a patient who tests positive for high‑risk HPV with detectable E6 oncoprotein?
How should a 48-year-old man with a bothersome right eye eyelid lesion be evaluated and managed?
For osteoporosis, how long should denosumab be administered and what parameters should be monitored during therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.